Phase I/II data for at Eli Lilly and Company’s non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, LOXO-305, show a high response rate among patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) who previously received covalent BTK inhibitor therapies. That indicates the drug could add to a treatment space with few options and whose current occupants can be cumbersome to give.
On 7 December at the American Society of Hematology virtual meeting, the drug maker's Loxo Oncology at Lilly division presented...








